Format

Send to

Choose Destination
F1000Res. 2016 Apr 19;5. pii: F1000 Faculty Rev-705. doi: 10.12688/f1000research.8012.1. eCollection 2016.

Recent advances in understanding and managing cholestasis.

Author information

1
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
2
Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Wien, Austria.

Abstract

Cholestatic liver diseases are hereditary or acquired disorders with impaired hepatic excretion and enterohepatic circulation of bile acids and other cholephiles. The distinct pathological mechanisms, particularly for the acquired forms of cholestasis, are not fully revealed, but advances in the understanding of the molecular mechanisms and identification of key regulatory mechanisms of the enterohepatic circulation of bile acids have unraveled common and central mechanisms, which can be pharmacologically targeted. This overview focuses on the central roles of farnesoid X receptor, fibroblast growth factor 19, and apical sodium-dependent bile acid transporter for the enterohepatic circulation of bile acids and their potential as new drug targets for the treatment of cholestatic liver disease.

KEYWORDS:

bile acid; cholestasis; hepatic; liver

Supplemental Content

Full text links

Icon for F1000 Research Ltd Icon for PubMed Central
Loading ...
Support Center